Premium
NRX Pharmaceuticals Inc (NRXP)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-... NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. Show more
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 PR Newswire WILMINGTON, Del., Feb. 6...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor PR Newswire MIAMI, Feb. 3, 2025 HOPE has announced plans to assemble a best-in-class global...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition PR Newswire MIAMI, Jan. 28, 2025 $25 million...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt PR Newswire WILMINGTON, Del...
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement PR Newswire WILMINGTON, Del., Jan. 21, 2025 Company received written...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market PR Newswire WILMINGTON, Del., Jan...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club PR Newswire MIAMI, Jan. 10, 2025 MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE...
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.17 | 5.9649122807 | 2.85 | 3.44 | 2.63 | 487406 | 2.97696976 | CS |
| 4 | -1.81 | -37.4741200828 | 4.83 | 5.4 | 2.63 | 706195 | 3.62193009 | CS |
| 12 | 1.72 | 132.307692308 | 1.3 | 6.01 | 1.1302 | 1271005 | 3.01985175 | CS |
| 26 | 0.94 | 45.1923076923 | 2.08 | 6.01 | 1.1 | 620117 | 2.8557898 | CS |
| 52 | -2.28 | -43.0188679245 | 5.3 | 7.333 | 1.1 | 724084 | 3.91488355 | CS |
| 156 | -24.38 | -88.9781021898 | 27.4 | 35.4 | 1.1 | 872503 | 6.88886096 | CS |
| 260 | -227.08 | -98.6875271621 | 230.1 | 262.4 | 1.1 | 1374804 | 64.23245184 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
